Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma.

Trial Profile

Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Panitumumab (Primary) ; Erlotinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 10 May 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 10 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top